Literature DB >> 18619919

Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy.

Patrick Yachimski1, Norman S Nishioka, Ethan Richards, Chin Hur.   

Abstract

BACKGROUND & AIMS: Patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma are at risk of progression to invasive carcinoma. Both esophagectomy and endoscopic ablation are treatment options. The aim of this study was to identify predictors of surgical versus endoscopic therapy at a tertiary center.
METHODS: An institutional database identified patients with Barrett's esophagus between 2003 and 2007. Demographic data and International Classification of Diseases-9th revision codes for esophagectomy, endoscopic ablation, as well as selected medical comorbidities were retrieved. Individual endoscopy, surgical, and pathology reports were reviewed.
RESULTS: Among 2107 individuals with Barrett's esophagus, 79 underwent esophagectomy and 80 underwent endoscopic ablation. The mean age was 63.1 +/- 10.6 years in the surgical group and 69.7 +/- 9.4 years in the ablation group (P < .0001). Among high-grade dysplasia/intramucosal carcinoma patients, 9 of 76 (12%) first seen by a gastroenterologist underwent esophagectomy, whereas 18 of 21 (86%) first seen by a surgeon underwent esophagectomy. In a logistic regression model, factors associated independently with esophagectomy were as follows: patient age of 60 or younger (odds ratio [OR], 4.95; 95% confidence interval [CI], 1.65-14.9), cancer stage T1sm or greater (OR, 16.0; 95% CI, 5.60-45.6), and initial consultation performed by a surgeon (vs gastroenterologist) (OR, 35.1; 95% CI, 9.58-129).
CONCLUSIONS: Patient age and cancer stage predict treatment modality for Barrett's esophagus with neoplasia. Treatment choice is influenced further by whether the initial evaluation is performed by a gastroenterologist or a surgeon.

Entities:  

Mesh:

Year:  2008        PMID: 18619919      PMCID: PMC3113490          DOI: 10.1016/j.cgh.2008.04.031

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  32 in total

1.  Hospital volume and surgical mortality in the United States.

Authors:  John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

2.  Does cancer risk affect health-related quality of life in patients with Barrett's esophagus?

Authors:  Lauren B Gerson; Nighat Ullah; Trevor Hastie; Mary K Goldstein
Journal:  Gastrointest Endosc       Date:  2007-01       Impact factor: 9.427

3.  Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus.

Authors:  Ganapathy A Prasad; Kenneth K Wang; Navtej S Buttar; Louis-Michel Wongkeesong; Kausilia K Krishnadath; Francis C Nichols; Lori S Lutzke; Lynn S Borkenhagen
Journal:  Gastroenterology       Date:  2007-02-07       Impact factor: 22.682

4.  Patient preferences for the management of high-grade dysplasia in Barrett's esophagus.

Authors:  Chin Hur; Eve Wittenberg; Norman S Nishioka; G Scott Gazelle
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

5.  Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett's oesophagus.

Authors:  Vijay Sujendran; Giuseppe Sica; Bryan Warren; Nicholas Maynard
Journal:  Eur J Cardiothorac Surg       Date:  2005-09-26       Impact factor: 4.191

6.  Surgical treatment of esophageal high-grade dysplasia.

Authors:  Michael F Reed; George Tolis; Barish H Edil; James S Allan; Dean M Donahue; Henning A Gaissert; Ashby C Moncure; John C Wain; Cameron D Wright; Douglas J Mathisen
Journal:  Ann Thorac Surg       Date:  2005-04       Impact factor: 4.330

7.  Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus.

Authors:  Ganapathy A Prasad; Kenneth K Wang; Navtej S Buttar; Louis-Michel Wongkeesong; Lori S Lutzke; Lynn S Borkenhagen
Journal:  Gastrointest Endosc       Date:  2007-01       Impact factor: 9.427

Review 8.  Barrett's esophagus.

Authors:  Gary W Falk
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

9.  Buried dysplasia and early adenocarcinoma arising in barrett esophagus after porfimer-photodynamic therapy.

Authors:  Mari Mino-Kenudson; Shinichi Ban; Masaya Ohana; William Puricelli; Vikram Deshpande; Michio Shimizu; Norman S Nishioka; Gregory Y Lauwers
Journal:  Am J Surg Pathol       Date:  2007-03       Impact factor: 6.394

10.  Quality of life in patients with various Barrett's esophagus associated health states.

Authors:  Chin Hur; Eve Wittenberg; Norman S Nishioka; G Scott Gazelle
Journal:  Health Qual Life Outcomes       Date:  2006-08-02       Impact factor: 3.186

View more
  8 in total

1.  Adherence to therapy for Barrett's esophagus-associated neoplasia.

Authors:  Lisa Cassani; James C Slaughter; Patrick Yachimski
Journal:  United European Gastroenterol J       Date:  2015-05-05       Impact factor: 4.623

2.  Expert pathology review and endoscopic mucosal resection alters the diagnosis of patients referred to undergo therapy for Barrett's esophagus.

Authors:  Katie Ayers; Chanjuan Shi; Kay Washington; Patrick Yachimski
Journal:  Surg Endosc       Date:  2013-02-07       Impact factor: 4.584

Review 3.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

4.  Evolving changes in the management of early oesophageal adenocarcinoma in a tertiary centre.

Authors:  N J O'Farrell; J V Reynolds; N Ravi; J O Larkin; V Malik; G F Wilson; C Muldoon; D O'Toole
Journal:  Ir J Med Sci       Date:  2012-12-16       Impact factor: 1.568

5.  Barrett's esophagus: where do we stand?

Authors:  Majid A Al Madi
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

Review 6.  Management controversies in Barrett's oesophagus.

Authors:  L Max Almond; Hugh Barr
Journal:  J Gastroenterol       Date:  2013-06-05       Impact factor: 7.527

7.  Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus.

Authors:  Cathy Bennett; Susi Green; John DeCaestecker; Max Almond; Hugh Barr; Pradeep Bhandari; Krish Ragunath; Rajvinder Singh; Janusz Jankowski
Journal:  Cochrane Database Syst Rev       Date:  2020-05-22

8.  Patient decision-making and clinical outcomes following endoscopic therapy or esophagectomy for Barrett's neoplasia.

Authors:  Robert Lockwood; Elissa Ozanne; Chin Hur; Patrick Yachimski
Journal:  Endosc Int Open       Date:  2017-11-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.